SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare trades higher on the bourses

27 Jan 2021 Evaluate

Cadila Healthcare is currently trading at Rs. 470.70, up by 3.85 points or 0.82% from its previous closing of Rs. 466.85 on the BSE.

The scrip opened at Rs. 470.50 and has touched a high and low of Rs. 472.55 and Rs. 460.00 respectively. So far 41416 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 212.70 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 489.30 and Rs. 455.35 respectively. The current market cap of the company is Rs. 48064.72 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.97% respectively.

Zydus Cadila has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients conducted in Mexico. In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidates Desidustat in the management of COVID-19.

Patients infected with COVID-19 have been reported to display signs of 'Hypoxia' leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators. The phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

948.10 5.55 (0.59%)
20-Apr-2026 09:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1234.80
Cipla 1241.25
Zydus Lifesciences 948.10
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×